Mangalam Drugs And Organics credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
10510581.287.968.3
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
10510578.687.065.6
1.02×1.02×0.54×0.65×—
1.02×1.02×0.53×0.64×—
−7.08×−7.08×2.27×5.06×—
−11.66×−7.03×2.19×5.00×—
−2.04×−2.04×1.29×0.20×—
50.6%50.6%35.3%39.3%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MANGALAM₹29.22

Mangalam Drugs And Organics Limited

· Pharma & Health
₹ CrorePeersBIOFILCHEMLASAVINEETLABORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹46.3 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt68.387.981.2105.5105.5
Net Debt65.687.078.6104.8104.8
Total Debt/Equity—0.650.541.021.02
Net Debt/Equity—0.640.531.021.02
Total Debt/EBITDA—5.062.27-7.08-7.08
Net Debt/EBITDA—5.002.19-7.03-11.66
Interest Coverage (EBIT/Interest)—0.201.29-2.04-2.04
Total Debt/Total Capital %—39.3135.2750.5850.58
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.